Targeting Discoidin Domain Receptors DDR1 and DDR2 overcomes matrix‐mediated tumor cell adaptation and tolerance to BRAF‐targeted therapy in melanoma

Myosin II Reactivation and Cytoskeletal Remodeling as a Hallmark and a Vulnerability in Melanoma Therapy Resistance

(2020) Jose L. Orgaz et al.   CANCER CELL

A Feed-Forward Mechanosignaling Loop Confers Resistance to Therapies Targeting the MAPK Pathway in BRAF-Mutant Melanoma

(2020) Christophe A. Girard et al.   CANCER RESEARCH

Robust gene expression programs underlie recurrent cell states and phenotype switching in melanoma

(2020) Jasper Wouters et al.   NATURE CELL BIOLOGY

CellMiner Cross-Database (CellMinerCDB) version 1.2: Exploration of patient-derived cancer cell line pharmacogenomics

(2020) Augustin Luna et al.   NUCLEIC ACIDS RESEARCH

Targeting DDR2 enhances tumor response to anti–PD-1 immunotherapy

(2019) Megan M. Tu et al.   Science Advances

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

(2019) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer cell-derived long pentraxin 3 (PTX3) promotes melanoma migration through a toll-like receptor 4 (TLR4)/NF-κB signaling pathway

(2019) M. Rathore et al.   ONCOGENE

Discoidin domain receptors: A promising target in melanoma

(2019) Coralie Reger de Moura et al.   Pigment Cell & Melanoma Research

GAPDH Overexpression in the T Cell Lineage Promotes Angioimmunoblastic T Cell Lymphoma through an NF-κB-Dependent Mechanism

(2019) Laura Mondragón et al.   CANCER CELL

Melanoma plasticity and phenotypic diversity: therapeutic barriers and opportunities

(2019) Florian Rambow et al.   GENES & DEVELOPMENT

Rho-mediated signaling promotes BRAF inhibitor resistance in de-differentiated melanoma cells

(2019) S. A. Misek et al.   ONCOGENE

DDR1 autophosphorylation is a result of aggregation into dense clusters

(2019) David S. Corcoran et al.   Scientific Reports

Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress

(2018) Jennifer Tsoi et al.   CANCER CELL

Inhibition of DDR1‐BCR signalling by nilotinib as a new therapeutic strategy for metastatic colorectal cancer

(2018) Maya Jeitany et al.   EMBO Molecular Medicine

Targeting the Proteasome-Associated Deubiquitinating Enzyme USP14 Impairs Melanoma Cell Survival and Overcomes Resistance to MAPK-Targeting Therapies

(2018) Robin Didier et al.   MOLECULAR CANCER THERAPEUTICS

Collagen abundance controls melanoma phenotypes through lineage-specific microenvironment sensing

(2018) Zsofia Miskolczi et al.   ONCOGENE

Inhibition of tumor–microenvironment interaction and tumor invasion by small-molecule allosteric inhibitor of DDR2 extracellular domain

(2018) Whitney R. Grither et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Clustering, Spatial Distribution, and Phosphorylation of Discoidin Domain Receptors 1 and 2 in Response to Soluble Collagen I

(2018) David A. Yeung et al.   JOURNAL OF MOLECULAR BIOLOGY

An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition

(2017) Helen L. Young et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Cell-derived matrices for studying cell proliferation and directional migration in a complex 3D microenvironment

(2017) Riina Kaukonen et al.   Nature Protocols

Fibronectin-guided migration of carcinoma collectives

(2017) Sandeep Gopal et al.   Nature Communications

Discoidin Domain Receptor 1 Mediates Myosin-Dependent Collagen Contraction

(2017) Nuno M. Coelho et al.   Cell Reports

Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy

(2016) Michael P. Smith et al.   CANCER CELL

Targeting DDR2 in head and neck squamous cell carcinoma with dasatinib

(2016) Anne von Mässenhausen et al.   INTERNATIONAL JOURNAL OF CANCER

sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance

(2016) Amanpreet Kaur et al.   NATURE

Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma

(2016) Chiara Ambrogio et al.   NATURE MEDICINE

Normal stroma suppresses cancer cell proliferation via mechanosensitive regulation of JMJD1a-mediated transcription

(2016) Riina Kaukonen et al.   Nature Communications

The Action of Discoidin Domain Receptor 2 in Basal Tumor Cells and Stromal Cancer-Associated Fibroblasts Is Critical for Breast Cancer Metastasis

(2016) Callie A.S. Corsa et al.   Cell Reports

DDR2 inhibition reduces migration and invasion of murine metastatic melanoma cells by suppressing MMP2/9 expression through ERK/NF- B pathway

(2015) B. Poudel et al.   ACTA BIOCHIMICA ET BIOPHYSICA SINICA

Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin β1/FAK Signaling

(2015) Eishu Hirata et al.   CANCER CELL

Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP/TAZ activation

(2015) M. H. Kim et al.   EMBO JOURNAL

BRAF Inhibition Generates a Host–Tumor Niche that Mediates Therapeutic Escape

(2015) Inna V. Fedorenko et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

The BRAFV600E inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells

(2015) Molly H. Jenkins et al.   MATRIX BIOLOGY

Cell shape and the microenvironment regulate nuclear translocation of NF- B in breast epithelial and tumor cells

(2015) J. E. Sero et al.   Molecular Systems Biology

NF-kB2 induces senescence bypass in melanoma via a direct transcriptional activation of EZH2

(2015) G M De Donatis et al.   ONCOGENE

Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance

(2015) Laetitia Seguin et al.   TRENDS IN CELL BIOLOGY

Tumour-derived SPARC drives vascular permeability and extravasation through endothelial VCAM1 signalling to promote metastasis

(2015) Mélanie Tichet et al.   Nature Communications

Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state

(2015) Annelien Verfaillie et al.   Nature Communications

The extracellular matrix modulates the hallmarks of cancer

(2014) M. W. Pickup et al.   EMBO REPORTS

Extracellular matrix assembly: a multiscale deconstruction

(2014) Janna K. Mouw et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma

(2014) Judith Müller et al.   Nature Communications

LIF Mediates Proinvasive Activation of Stromal Fibroblasts in Cancer

(2014) Jean Albrengues et al.   Cell Reports

Discovery of a Potent and Selective DDR1 Receptor Tyrosine Kinase Inhibitor

(2013) Hyung-Gu Kim et al.   ACS Chemical Biology

NF- B2/p52 Induces Resistance to Enzalutamide in Prostate Cancer: Role of Androgen Receptor and Its Variants

(2013) N. Nadiminty et al.   MOLECULAR CANCER THERAPEUTICS

Discoidin domain receptor tyrosine kinases: new players in cancer progression

(2012) Rajeshwari R. Valiathan et al.   CANCER AND METASTASIS REVIEWS

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

(2012) Ravid Straussman et al.   NATURE

Systematic classification of melanoma cells by phenotype-specific gene expression mapping

(2012) Daniel S. Widmer et al.   Pigment Cell & Melanoma Research

Overview of the Matrisome--An Inventory of Extracellular Matrix Constituents and Functions

(2011) R. O. Hynes et al.   Cold Spring Harbor Perspectives in Biology

Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer

(2011) Peter S. Hammerman et al.   Cancer Discovery

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

(2010) Ramin Nazarian et al.   NATURE

Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib

(2008) Elizabeth Day et al.   EUROPEAN JOURNAL OF PHARMACOLOGY